CureLab Veterinary
CureLab Veterinary is a biotechnology company focused on the development of gene-based therapies targeting cancer and chronic inflammatory diseases in companion animals, such as dogs, cats, and horses. Utilizing advances in comparative medicine and translational immunology, the company applies a plasmid-based platform to stimulate anti-cancer immune responses, modulate tumor microenvironments, and mitigate chronic inflammation. Clinical research leverages academic partnerships and a robust intellectual property portfolio, pursuing efficient regulatory approval pathways in major markets, including the US and Europe. Recent studies suggest broader applications in pain management and cross-species translational potential.
Industries
N/A
Products
A gene therapy platform using circular DNA plasmid encoding p62/SQSTM1, delivered via intramuscular injection, aimed at enhancing anti-cancer immune responses, remodeling the tumor microenvironment, and modulating inflammation and chronic pain.
A gene therapy platform using circular DNA plasmid encoding p62/SQSTM1, delivered via intramuscular injection, aimed at enhancing anti-cancer immune responses, remodeling the tumor microenvironment, and modulating inflammation and chronic pain.
Services
Collaboration opportunities for academic and private veterinary clinics to participate in clinical research programs focusing on gene-based therapies for cancer, chronic inflammatory diseases, and pain in companion animals.
Collaboration opportunities for academic and private veterinary clinics to participate in clinical research programs focusing on gene-based therapies for cancer, chronic inflammatory diseases, and pain in companion animals.
Expertise Areas
- Comparative oncology
- Veterinary gene therapy
- Translational medicine
- Chronic inflammatory disease research
Key Technologies
- Gene therapy using plasmid DNA
- Cancer immunotherapy
- Chronic inflammation modulation
- Mesenchymal stem cell modulation
Key People
Founder, Chairman of the Board, Interim CEO
President
Executive Vice-President
VP of R&D
Controller
Director of Basic Research
Founder, Chairman of the Board, Interim CEO
President
Executive Vice-President
VP of R&D
Controller
Director of Basic Research
News & Updates
Gene and anti-inflammation therapy patents granted in the USA, Europe, Asia, Latin America, and additional regions.
Secured exclusive global rights for all veterinary applications of gene therapy intellectual property derived from human-focused research.
Received $3 million investment to advance R&D and regulatory programs.
Peer-reviewed study in Frontiers in Veterinary Science reports high efficacy of plasmid therapy in reducing osteoarthritis pain in dogs, with no significant side-effects.
Feature on open-label pilot study showing that plasmid DNA therapy provided significant pain relief in dogs with osteoarthritis, with implications for non-opioid pain management.
Article explored the translational promise of gene therapy resetting aging mesenchymal stem cells for canine arthritis and possible human application.
Gene and anti-inflammation therapy patents granted in the USA, Europe, Asia, Latin America, and additional regions.
Secured exclusive global rights for all veterinary applications of gene therapy intellectual property derived from human-focused research.
Received $3 million investment to advance R&D and regulatory programs.
Peer-reviewed study in Frontiers in Veterinary Science reports high efficacy of plasmid therapy in reducing osteoarthritis pain in dogs, with no significant side-effects.
Feature on open-label pilot study showing that plasmid DNA therapy provided significant pain relief in dogs with osteoarthritis, with implications for non-opioid pain management.
Article explored the translational promise of gene therapy resetting aging mesenchymal stem cells for canine arthritis and possible human application.